Inactive Instrument

SciSparc Ltd. OTC Markets

TRPXD

US80909J1025

Therapix Biosciences Ltd. has Changed its Name to SciSparc Ltd

January 28, 2021 at 02:36 pm

Therapix Biosciences Ltd. changed its name to SciSparc Ltd.

Latest news about SciSparc Ltd.

Scisparc Signs Non-Binding Letter of Intent for Out-Licensing of Potential Pain Treatment	01:26pm	MT
SciSparc Receives Nasdaq Noncompliance Notice	07-16	MT
SciSparc Seeks Patent for Obesity Drug Ingredient's Composition	07-16	MT
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss	07-16	CI
SciSparc Signs Non-Binding Letter of Intent to Spin Off Advanced Clinical Stage Pharmaceutical Portfolio	07-08	MT
SciSparc Ltd. Secures Strategic Advantage with Grant of European Patent	06-03	CI
SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd.	04-10	CI
Tranche Update on SciSparc Ltd.'s Equity Buyback Plan announced on July 7, 2022.	04-01	CI
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
SciSparc Ltd. Receives Another Patent, Strengthening its Core Technology in Canada	03-18	CI
SciSparc Ltd. Announces Successfully Dosed the First Patient in Its SCI-210 Clinical Trial At the Soroka Medical Center for Pediatric Patients	03-14	CI
Top Premarket Gainers	03-08	MT
SciSparc Ltd. Announces Enrollment of First Patient for Its Clinical Trial for Children with Autism Spectrum Disorder	03-08	CI
Scisparc Ltd. Granted Patent for Core Technology in Multiple Jurisdictions in Europe	03-07	CI
SciSparc Ltd. Receives Canadian Patent for Opioids Reduction Use in Pain Management Technology	03-06	CI
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	02-29	CI
Clearmind Medicine Submits Three International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds	02-27	MT
Clearmind Medicine Submits Three International Patent Applications for Next Generation Psychedelic-Based Compounds	02-20	MT
Scisparc Initiates Autism Spectrum Disorder Study	01-29	MT
Top Midday Decliners	01-29	MT
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder	01-29	CI
Top Midday Gainers	01-24	MT
SciSparc Ltd. announced that it expects to receive $20 million in funding	01-23	CI
SciSparc Ltd. and Clearmind Medicine Inc. Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments	01-04	CI
Clearmind Medicine's Novel Obesity Drug Shows Positive Results in Pre-Clinical Trial	12-01	MT

Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.35B
OTSUKA HOLDINGS CO., LTD.	+38.38%	24.34B
SANDOZ GROUP AG	+27.09%	16.51B
CIPLA LIMITED	+21.19%	14.6B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.27B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.63%	6.57B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.08%	5.76B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals